Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Japanese R&D of autoimmune disorder medicines company seeks USD 12m pre-IPO financing.
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||autoimmune disorders medicines - Phase II clinical trial - USD 33 m secured|
The Japanese company is mainly engaged in R&D of medicines for autoimmune disorders and is also preparing to carry out R&D of cancer medicines related to harmonic T cells. At present, one of the two medicines in the pipeline has entered Phase II clinical trial. The company was restructured in 2018 and registered in Taiwan. Its total investment exceeds USD 33 million. It seeks pre-IPO financing of USD 12 million (USD 5 million has been injected), and then plans to be listed in Taiwan in 2023.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us